Single nucleotide polymorphisms in the HIF-1α gene and chemoradiotherapy of locally advanced rectal cancer

Genetic Variations in the HIF1A Gene Modulate Response to Adjuvant Chemotherapy after Surgery in Patients with Colorectal Cancer

“…In our study, we for the first time found that the patients with CC genotype of rs2057482 and CT/TT genotypes of rs2301113 can obviously benefit from adjuvant chemotherapy. Similarly, a previous study (Havelund et al, 2012) have analyzed the correlation between the rs2057482 and response to chemoradiotherapy (CRT) in rectal cancer and found positive results. However, this finding has not been replicated in validation cohort.…”

HIF1α Genetic Variants and Protein Expressions Determine the Response to Platinum Based Chemotherapy and Clinical Outcome in Patients with Advanced NSCLC

“…The polymorphic S582 and T588 variants, with amino acid transition, may enhance the transcriptional activity of HIF-1α gene because of structural changes. The polymorphisms at C1772T (P582S) and G1790A (A588T) of the HIF-1α gene have been previously identified in esophageal squamous cell carcinomas, breast cancer, colorectal and prostate cancers and breast [27,36,37,38,39,40,41]. The impact of HIF-1α gene polymorphism and HIF mRNA and protein expression has been reported previously HIF-1α mRNA expression levels were significantly higher in prostate cancer patients with the TT genotype compared with the CC genotype.…”

Germline and Somatic Pharmacogenomics to Refine Rectal Cancer Patients Selection for Neo-Adjuvant Chemoradiotherapy

“…The hypoxia inducible factor 1 subunit alpha (HIF-1a, encoded by HIF1A) is an important mediator of hypoxiainduced radio-resistance. The association between hypoxiarelated markers (i.e., HIF1A rs11549465, rs11549467, and rs2057482 polymorphism) and response to nCRT was analyzed but no significant association were highlighted (Havelund et al, 2012).…”